RainDance Technologies Appoints Kathy Ordonez as CEO
News Jul 20, 2016
RainDance Technologies, Inc., has announced the appointment of Kathy Ordoñez as Chief Executive Officer. She continues in her current role as Chairman of the Board of Directors. Former CEO Roopom Banerjee has left the Company to pursue other opportunities.
After joining the Board of RainDance in July 2014, Ms. Ordoñez established and led the Science and Innovation Committee for the Board and was named the Company’s Chairman of the Board in September 2015. She has subsequently provided guidance to the Company’s management team and has worked closely with the Company’s investors while leading the Company’s product strategy and development efforts.
“Kathy Ordoñez is highly respected in the life sciences and diagnostics industry,” said Michael Hunkapiller, Ph.D., a Board Director at RainDance Technologies. “Kathy has brought new focus to RainDance over the past two years, and our board and investors believe her relationship with the team, her creative mindset, and deep industry experience will advance the adoption and reach of RainDance’s products and technologies.”
Ms. Ordoñez brings more than 30 years of experience in the life sciences and diagnostics industries. As Senior Vice President at Quest Diagnostics, she was initially responsible for leading the company’s R&D effort and later provided oversight to multiple businesses commercializing diagnostic products and testing services. She joined Quest Diagnostics as part of its acquisition of Celera Corporation in 2011. Ms. Ordoñez was previously the Chief Executive Officer at Celera and a founder of Celera Diagnostics. Under her leadership, Celera became the leading producer of genetic testing products for HIV resistance, cystic fibrosis and high complexity tissue transplantation. Earlier in her career, Ms. Ordoñez held several senior positions at Hoffmann La-Roche, overseeing the formation of Roche Molecular Systems, where she served as President and Chief Executive Officer, and led the wide-scale commercial application of the Polymerase Chain Reaction (PCR) technology to the research, diagnostic and forensic fields.
“It is a privilege to lead the RainDance team, whose members invented and developed key biological applications of droplet technology,” said Ms. Ordoñez. “I look forward to building on my relationships with RainDance team members and our business and research partners to launch new products incorporating these innovations over the coming months.”
Giant Viruses Invent Their Own GenesNews
Three new members have been isolated and added to the Pandoravirus family. This strange family of viruses, with their giant genomes and many genes with no known equivalents, surprised scientists when they were discovered a few years ago. This new study notes that pandoraviruses appear to be factories for new genes – and therefore new functions.
Therapeutic CRISPR Could Be Cancer RiskNews
Therapeutic use of gene editing with the so-called CRISPR-Cas9 technique may inadvertently increase the risk of cancer, according to a new study. Researchers say that more studies are required in order to guarantee the safety of these ‘molecular scissors’ for gene-editing therapies.
Who Owns the Ocean? One Company Has Registered Half of All Marine Gene PatentsNews
A single corporation has registered nearly half of all existing patents associated with genes from marine organisms, according to a new study. Researchers from the University of British Columbia and the Stockholm Resilience Centre examined the patents associated with marine species and found that BASF, the world’s largest chemical manufacturer, has registered 47 per cent of the 12,998 genetic sequences from 862 marine species.